Unique Interplay Between Molecular miR-181b/d Biomarkers and Health Related Quality of Life Score in the Predictive Glioma Models.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • Subject Terms:
      Biomarkers, Tumor* ; Quality of Life*; Glioma/*epidemiology ; Glioma/*genetics ; MicroRNAs/*genetics; Adult ; Aged ; Aged, 80 and over ; DNA Methylation ; DNA Modification Methylases/genetics ; DNA Repair Enzymes/genetics ; Female ; Glioma/diagnosis ; Glioma/therapy ; Humans ; Isocitrate Dehydrogenase/genetics ; Karnofsky Performance Status ; Male ; Middle Aged ; Prognosis ; Promoter Regions, Genetic ; Tumor Suppressor Proteins/genetics ; Young Adult
    • Abstract:
      In the last decade, an increasing amount of research has been conducted analyzing microRNA expression changes in glioma tissue and its expressed exosomes, but there is still sparse information on microRNAs or other biomarkers and their association with patients' functional/psychological outcomes. In this study, we performed a combinational analysis measuring miR-181b and miR-181d expression levels by quantitative polymerase chain reaction (qPCR), evaluating isocitrate dehydrogenase 1 ( IDH1 ) single nucleotide polymorphism (SNP), and O-6-methylguanine methyltransferase ( MGMT ) promoter methylation status in 92 post-surgical glioma samples and 64 serum exosomes, including patients' quality of life evaluation applying European Organization for Research and Treatment of Cancer (EORTC) questionnaire for cancer patients (QLQ-30), EORTC the Brain Cancer-Specific Quality of Life Questionnaire (QLQ-BN20), and the Karnofsky performance status (KPS). The tumoral expression of miR-181b was lower in grade III and glioblastoma, compared to grade II glioma patients ( p < 0.05). Additionally, for the first time, we demonstrated the association between miR-181 expression levels and patients' quality of life. A positive correlation was observed between tumoral miR-181d levels and glioma patients' functional parameters ( p < 0.05), whereas increased exosomal miR-181b levels indicated a worse functional outcome ( p < 0.05). Moreover, elevated miR-181b exosomal expression can indicate a significantly shorter post-surgical survival time for glioblastoma multiforme (GBM) patients. In addition, both tumoral and exosomal miR-181 expression levels were related to patients' functioning and tumor-related symptoms. Our study adds to previous findings by demonstrating the unique interplay between molecular miR-181b/d biomarkers and health related quality of life (HRQOL) score as both variables remained significant in the predictive glioma models.
    • References:
      Mol Cancer Res. 2015 Sep;13(9):1347-57. (PMID: 26013170)
      Cell Mol Neurobiol. 2014 Jan;34(1):17-30. (PMID: 24213247)
      J Neurooncol. 2011 Jun;103(2):317-24. (PMID: 20845061)
      Sci Rep. 2015 Jan 27;5:7979. (PMID: 25623281)
      Eur J Cancer. 2019 Jul;116:190-198. (PMID: 31203194)
      Cancer. 1984 May 1;53(9):2002-7. (PMID: 6704925)
      Nat Rev Clin Oncol. 2018 Sep;15(9):541-563. (PMID: 29784926)
      J Neurooncol. 2009 Jul;93(3):325-32. (PMID: 19159078)
      Sci Rep. 2015 Jun 10;5:11251. (PMID: 26059512)
      Value Health. 2019 Nov;22(11):1303-1310. (PMID: 31708068)
      Surg Neurol. 2009 Mar;71(3):299-303, discussion 303. (PMID: 18786716)
      RNA. 2013 Apr;19(4):552-60. (PMID: 23431408)
      Sci Rep. 2017 Apr 7;7(1):732. (PMID: 28389653)
      Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. (PMID: 18663219)
      Nat Rev Mol Cell Biol. 2014 Sep;15(9):565-76. (PMID: 25118717)
      Qual Life Res. 2012 Feb;21(1):143-53. (PMID: 21598062)
      Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8. (PMID: 16039986)
      J Neurooncol. 2017 Jan;131(2):385-391. (PMID: 27830477)
      Cancers (Basel). 2019 Mar 04;11(3):. (PMID: 30836600)
      Oncol Res. 2017 Jul 5;25(6):947-957. (PMID: 27938503)
      J Neurosurg. 2016 Apr;124(4):989-97. (PMID: 26430849)
      Cancers (Basel). 2018 Dec 22;11(1):. (PMID: 30583549)
      Handb Clin Neurol. 2016;134:267-85. (PMID: 26948360)
      Neuroreport. 2015 Jan 21;26(2):66-73. (PMID: 25494473)
      Sci Rep. 2017 Jul 14;7(1):5467. (PMID: 28710497)
      Neuro Oncol. 2010 Nov;12(11):1162-6. (PMID: 20511193)
      Blood. 2012 Jan 19;119(3):646-8. (PMID: 22262739)
      RNA Biol. 2012 Jun;9(6):850-9. (PMID: 22699556)
      J Neurochem. 2014 Jun;129(5):877-83. (PMID: 24460924)
      Neuro Oncol. 2012 Jun;14(6):712-9. (PMID: 22570426)
      Acta Pharmacol Sin. 2018 Sep;39(9):1405-1413. (PMID: 29417946)
      Neuro Oncol. 2015 Jan;17(1):160-6. (PMID: 24903904)
      Comput Biol Med. 2014 Sep;52:82-7. (PMID: 25016292)
      J Clin Oncol. 2017 Jul 20;35(21):2402-2409. (PMID: 28640706)
      J Cell Biochem. 2017 Dec;118(12):4548-4557. (PMID: 28475287)
      J Cancer Surviv. 2017 Aug;11(4):447-452. (PMID: 28194640)
      Oncologist. 2020 Apr;25(4):e722-e732. (PMID: 32297435)
      Cancers (Basel). 2013 Oct 23;5(4):1306-31. (PMID: 24202447)
      Psychoneuroendocrinology. 2016 Jan;63:362-9. (PMID: 26555429)
      Oncotarget. 2016 May 10;7(19):28195-206. (PMID: 27057640)
      PLoS One. 2011;6(12):e28592. (PMID: 22174842)
      Sci Rep. 2015 Aug 18;5:13072. (PMID: 26283154)
      Eur J Cancer. 2010 Apr;46(6):1033-40. (PMID: 20181476)
    • Grant Information:
      S-MIP-17-108 Lietuvos Mokslo Taryba
    • Contributed Indexing:
      Keywords: exosomes; glioblastoma; miR-181; prognosis; quality of life
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (MIRN-181 microRNA, human)
      0 (MicroRNAs)
      0 (Tumor Suppressor Proteins)
      EC 1.1.1.41 (Isocitrate Dehydrogenase)
      EC 1.1.1.42. (IDH1 protein, human)
      EC 2.1.1.- (DNA Modification Methylases)
      EC 2.1.1.63 (MGMT protein, human)
      EC 6.5.1.- (DNA Repair Enzymes)
    • Publication Date:
      Date Created: 20201014 Date Completed: 20210226 Latest Revision: 20210226
    • Publication Date:
      20231215
    • Accession Number:
      PMC7589546
    • Accession Number:
      10.3390/ijms21207450
    • Accession Number:
      33050332